Source comparison
BPC-157 Differs from PRP Therapy — Full Comparison
Mechanism Synthetic peptide upregulates VEGF and nitric oxide pathways Autologous platelet growth factors (PDGF, TGF-, IGF-1) activate endogenous repair BPC-157 introduces exogenous signal; PRP amplifies your own biology Source Material Pharmaceutical synthes
This comparison does not assign a generated winner or score.
- Mechanism
- Synthetic peptide upregulates VEGF and nitric oxide pathways
- Autologous platelet growth factors (PDGF, TGF-β, IGF-1) activate endogenous repair
- BPC-157 introduces exogenous signal; PRP amplifies your own biology
- Source Material
- Pharmaceutical synthesis (SPPS), 15-amino-acid peptide
- Patient's own blood, centrifuged to concentrate platelets 3–10×
- PRP = zero rejection risk; BPC-157 = synthetic foreign molecule
- Dosing Frequency
- Daily injections for 14–28 days (animal protocols)
- Single injection or 2–4 injections spaced weeks apart
- BPC-157 requires sustained daily administration; PRP is episodic
- FDA Status
- Not approved for any human use; research chemical only
- FDA-cleared as Class II device under 21 CFR 1271
- PRP is legal clinical practice; BPC-157 is legally ambiguous
- Human Clinical Trials
- Zero Phase 3 trials; animal data only
- 150+ RCTs across orthopedic indications
- PRP has extensive human safety/efficacy data; BPC-157 does not
- Cost Range
- $80–$300 per vial (4–8 week supply, grey market pricing)
- $500–$2500 per session depending on clinic and area treated
- BPC-157 cheaper per course but sold outside regulated channels